Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab

Sponsor: Federico II University
Study ID: NCT04138420
Status: Completed

Conditions

Exudative Age-related Macular Degeneration

Eligibility Criteria

Sex: ALL
Age: 50 Years - 80 Years
Healthy Volunteers: Not accepted

Interventions

Bevacizumab Injection — DRUG
Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)

Study Details

This study evaluates the retinal and vascular features in patients with macular degeneration under the effects of Bevacizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.

Key Dates

First listed: Oct 24, 2019
Start date: Jan 25, 2017
Status verified: Oct 2019
Primary completion: Oct 25, 2017
Completion: Oct 30, 2017

Study Design

Enrollment: 38 participants (actual)

Arms

Arm: Patients receiving Bevacizumab
Bevacizumab, intravitreal injection, three monthly, dosage: 1.25 mg/0.05 mL.

Primary Outcome Measure

Study of retinal structural features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab [ Time Frame: three months ]